Sign in
WF

WEBSTER FINANCIAL CORP (WBS)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 delivered record diluted EPS of $1.54 on revenue of $732.6M, with ROA 1.27% and ROATCE 17.64%, supported by broad-based loan (+2.6% q/q) and deposit (+2.8% q/q) growth .
  • EPS modestly beat Wall Street consensus by ~$0.02*, while revenue exceeded by ~$5.3M*; NIM compressed 4 bps q/q to 3.40% as new originations skewed higher-quality, lower-spread assets .
  • Management guided Q4 net interest income to be “effectively flat” vs Q3 and Q4 NIM ~3.35% (lower end of prior 3.35–3.40% range); deposits expected ~1% seasonal decline (ex-public funds: ~+1%) and fees to step back without the legal settlement .
  • Strategic themes: accelerating HSA Bank opportunity from ACA rule changes (D2C enrollment, cross-sell) ; private credit JV with Marathon is operational with positive early pipeline/referrals ; continued strong capital and buybacks (2.2M shares repurchased) .
  • Additional catalysts: Board declared $0.40 common dividend and reduced prime lending rate to 7.00% effective Oct 30, 2025, aligning with broader rate dynamics .

What Went Well and What Went Wrong

What Went Well

  • Record EPS with strong returns: EPS $1.54, ROA 1.27%, ROATCE 17.64%; CEO: “Webster continues to exhibit strong financial results” . CFO: “We are proud to deliver record quarterly EPS” .
  • Broad-based growth: period-end loans reached $55.1B (+$1.4B q/q) and deposits $68.2B (+$1.9B q/q), with diverse deposit inflows across Commercial, HFS and seasonal public funds .
  • HSA Bank/Ametros momentum and ACA expansion: increased addressable market for HSAs, D2C enrollment push, and tech investments to capitalize in 2026; “refinements will streamline and optimize the enrollment process” .

What Went Wrong

  • NIM pressure and spread compression: NIM fell to 3.40% (−4 bps q/q) due to lower spreads on new loan originations and mix shift to high-quality, lower-yield assets; CRE originations in “low 6%” yield range .
  • Non-interest expense rose q/q to $356.7M (+$11M), driven by incentive accruals and continued investment in people/technology/risk; efficiency ratio ticked up to 45.79% .
  • Asset quality metrics stable but resolution slower than hoped: NCOs 0.28% (near low end of normalized 25–35 bps), NPL ratio ~0.99%; management “disappointed” by slower resolution in office/healthcare-services exposures .

Financial Results

MetricQ3 2024Q1 2025Q2 2025Q3 2025
Revenue ($USD Millions)$647.6 $704.8 $715.8 $732.6
Diluted EPS ($)$1.10 $1.30 $1.52 $1.54
Net Interest Margin (%)3.36 3.48 3.44 3.40
ROA (%)1.01 1.15 1.29 1.27
Efficiency Ratio (%)45.49 45.79 45.40 45.79
CET1 (%)11.23 11.26 11.33 11.40
Loans (Period-End, $USD Billions)$51.9 $53.1 $53.7 $55.1
Deposits (Period-End, $USD Billions)$64.5 $65.6 $66.3 $68.2
TBV per Share ($)$33.26 $33.97 $35.13 $36.42

Segment Operating Results (Q3 2025 vs Q3 2024)

SegmentOperating Revenue ($USD Millions) Q3 2024Operating Revenue ($USD Millions) Q3 2025PTPP/Pre-tax Net Revenue ($USD Millions) Q3 2024PTPP/Pre-tax Net Revenue ($USD Millions) Q3 2025
Commercial Banking$371.7 $362.2 $270.8 $253.6
Healthcare Financial Services (HSA Bank + Ametros)$120.5 $127.3 $66.5 $72.9
Consumer Banking$230.4 $239.4 $114.2 $114.0

Selected KPIs

KPIQ3 2024Q1 2025Q2 2025Q3 2025
Net Charge-offs / Avg Loans (%)0.27 0.42 0.27 0.28
NPLs / Total Loans (%)0.82 1.06 1.00 0.99
ACL / Total Loans (%)1.32 1.34 1.35 1.32
ACL / NPLs (%)161.60 126.39 135.08 133.82
Core Deposits / Total Deposits (%)88.5 88.5 88.1 88.9
Loan-to-Deposit Ratio (%)80.5 80.9 80.9 80.8

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Net Interest Margin (NIM)Q4 20253.35%–3.40% (prior call) ~3.35% Lowered to low end
Net Interest Income (NII)Q4 2025N/A (not quantified here)Effectively flat vs Q3 Maintained stable outlook
DepositsQ4 2025Seasonal outflows typically~−1% seasonal decline; ex-public funds ~+1% growth Clarified seasonality
FeesQ4 2025N/AStep back (no legal settlement benefit) Lower
Subordinated NotesQ4 2025N/AIntend to redeem 2029 and 2030 notes, subject to market New action
Category 4 Regulatory InvestmentsMedium term~$60M over 3 years (run rate uplift) If threshold lifted, redeploy and pace/spread costs Potentially lowered / reallocated
Dividend (Common)Q4 2025$0.40$0.40 declared; payable Nov 20, 2025 Maintained
Prime Lending RateEffective Oct 30, 20257.25%7.00% Lowered

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 & Q2 2025)Current Period (Q3 2025)Trend
Loan growth pipelinesQ1: grew loans; increased ACL for macro uncertainty ; Q2: “impressive financial and strategic results”, asset quality improved Broad growth across all categories; CRE pick-up; originations robust Improving throughput
NIM and spreadsQ1: NIM 3.48% ; Q2: 3.44% with discrete benefit NIM 3.40%; compression from higher-quality, lower-spread originations; CRE yields low-6% Gradual pressure
Deposits & mixQ1/Q2: core deposit strength; seasonality Diverse growth incl. public funds; brokered CD use tactical, 2–4% range Stable, tactical
HSA Bank & ACA expansionQ1: HFS deposits/footings growth ; Q2: continued growth ACA bronze/catastrophic eligibility expands addressable market; D2C push and tech investments Accelerating opportunity
Private credit JV (Marathon)N/A in Q1; initial commentary in Q2 investor events (implied)JV fully operational; pipeline approvals/placements; positive referrals Scaling up
Regulatory tailoring (Category 4)Q1/Q2: building risk infrastructure Expect potential threshold lift; redeploy ~$60M over 3 years to growth/digitization Constructive
Asset quality focusQ1: ACL build; NPL uptick Criticized loans down >7%; NPLs flat; concentration in office/healthcare services Gradual improvement signals
M&A stanceQ1/Q2: organic focus Not pursuing whole-bank M&A; small healthcare adjacencies possible; sale not proactive Unchanged
NYC macro/politicsN/A in Q1/Q2Base case: limited near-term impact on credit/business; growth drivers not NYC-specific Monitored, manageable

Management Commentary

  • CEO: “It is appropriate that on Webster’s 90th anniversary, the consistency and excellence Webster has delivered since its founding persists.”
  • CFO: “We are proud to deliver record quarterly EPS… tangible book value grew 3.7% over the prior quarter.” (TBV: $36.42 vs $35.13) .
  • COO: On HSA Bank/ACA expansion: “CMS clarified… more expansive than originally thought… refinements will streamline and optimize the enrollment process” with expected D2C opportunity in 2026 .
  • CFO on outlook: “Expecting net interest income to be effectively flat… Q4 NIM right around 3.35%… fees likely to step back a bit” .

Q&A Highlights

  • Private credit/NBFI exposure: ~$6B, concentrated in fund banking and lender finance with zero losses/classified/non-accruals over 10 years; safeguards against fraud include counterparties, diligence, monitoring, low LTVs .
  • Deposit mix strategy: prefer InterSync/HSA/Ametros deposits over brokered; brokered used tactically to offset public fund seasonality (2–4% of deposits) .
  • Loan growth trajectory: pipeline strong; Q4 growth expected solid but below Q3 due to higher prepayments and payoffs; focus on core C&I .
  • NIM drivers: credit spread compression and higher-quality loan mix; recent CRE originations in low-6% yield range; aim to balance growth and spread .
  • Capital deployment: buybacks paced by loan growth and healthcare adjacencies; CET1 11.4% above targets .

Estimates Context

MetricConsensus EstimateActualSurprise
EPS (Q3 2025)$1.524*$1.54 +$0.016*
Revenue (Q3 2025)$727.3M*$732.6M +$5.3M*
EPS (Q2 2025)$1.427*$1.52 +$0.093*
Revenue (Q2 2025)$712.2M*$715.8M +$3.6M*
EPS (Q1 2025)$1.380*$1.30 −$0.080*
Revenue (Q1 2025)$701.5M*$704.8M +$3.3M*

Values marked with * retrieved from S&P Global via analyst estimates.

  • Target Price Consensus Mean ~$70.76*; EPS estimates based on ~18 contributors for Q3; revenue estimates ~10 contributors for Q3* (context only).
  • Implications: Q3 beat modest on EPS and revenue; NIM compression and Q4 NII/NIM guide suggests estimate revisions could shift down for NIM assumptions and fee income (no repeat of legal settlement), partially offset by loan/deposit growth and ACA/HSA tailwinds .

Key Takeaways for Investors

  • Quality growth with record EPS: balance-sheet expansion across all loan categories and diversified deposits underpin sustained ROA/ROATCE; buybacks and TBV accretion add equity value .
  • Near-term margin caution: NIM trending to ~3.35% in Q4 as originations skew to high-quality, lower spread; expect flattish NII and softer fees absent one-offs—position accordingly for modest estimate drift .
  • Structural fee/deposit optionality: ACA-driven D2C HSA expansion and Ametros platform offer medium-term deposit and fee growth vectors beyond core banking cyclicality .
  • Private credit JV leverages sponsor finance without outsized balance-sheet risk; early signs positive and may catalyze on/off-balance sheet opportunities into 2026 .
  • Credit holding steady with improving criticized trends; watch office/healthcare services resolution pace, but NCOs remain near low end of normalized range .
  • Liquidity/capital robust (CET1 11.40%); tactical brokered CDs offset seasonal swings; dividend maintained and prime rate reduced, supportive of deposit pricing flexibility .
  • Trading lens: modest beat vs consensus, but guidance tilts conservative on margin/fees—expect stock to key off sustainability of loan/deposit growth, ACA/HSA visibility, and clarity on category 4 regulatory tailwinds at January guidance update .